DarioHealth

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. The firm solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DarioHealth excels in Q4 2022 with B2B growth and strategic partnerships

DarioHealth's Q4 2022 marked strong financial performance and operational efficiency gains.
Strategic focus on B2B model and multi-condition management driving revenue growth.
Challenges include managing increased expenses and maintaining high gross margin targets.
Opportunities lie in expanding client base, strategic integrations, and revenue diversification.

DarioHealth reports revenue growth and strategic partnerships driving future expansion

DarioHealth's Q1 2023 performance showed revenue growth, improved margins, and strategic focus on B2B.
Strong partnerships with Amwell and Sanofi position the company for multi-condition agreements and revenue growth.
Operational challenges in DTC margins and user comparison require attention for sustained growth.
Opportunities lie in hospitalization reduction, revenue growth from partnerships, and market expansion through Aetna launch.

DarioHealth reports steady Q2 performance, eyes growth through partnerships

DarioHealth's Q2 2023 performance showcased steady B2B2C ARR growth despite flat revenue, with improving gross margins and reduced operating losses, supported by a strong cash position.
The company's strengths lie in strategic partnerships, market fit, and operational efficiency, while facing challenges in revenue growth rates and optimizing expenses.
Opportunities ahead include revenue growth through partnerships and new product launches, leveraging AI for engagement and cost efficiencies, and sustaining a software-driven business model.

DarioHealth reports growth in Q3 2023, eyes revenue diversification

DarioHealth's Q3 2023 showed growth and improved financial metrics.
Strategic partnerships and revenue diversification are key strengths.
Challenges include predicting revenue recognition and cost management.
Opportunities lie in revenue growth and becoming cash flow positive.

DarioHealth reports robust Q4 results, eyes growth through strategic acquisitions

DarioHealth's strong Q4 performance and strategic acquisitions position the company for growth in 2024 and 2025, with a focus on profitability and revenue expansion.
While facing challenges in revenue scaling and cost reduction, the company's strengths in cash position, innovation, and leadership integration provide a solid foundation for success.
Opportunities lie in revenue growth from partnerships and acquisitions, integration synergies, and advancements in digital solutions, driving DarioHealth's path to market differentiation and financial success.

DarioHealth excels in Q1 2024, eyes profitability post Twill merger

DarioHealth's strong Q1 performance driven by B2B2C growth, poised for profitability post Twill merger. Focus on product integration and revenue expansion in key channels.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

NEW YORK, June 8, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, today announced the consummation of the previously announced acquisition of PsyInnovations, Inc. (dba wayForward) through the merger of PsyInnovations into DarioHealth's wholly-owned subsidiary, WF Merger Sub, Inc., which changed its name to PsyInnovations, Inc. in connection with the merger.  Under the Agreement and Plan of Merger, dated as of May 15, 2021, the Company paid, or will pay, aggregate consideration ("Merger Consideration") of (A) $6.0 million in cash and (B) up to $24.0 million in shares of Company common stock, par value $0.0001 per share (the "Common Stock"), including up to $5.0 million structured as an earn-out payable in shares of Common Stock if behavioral health revenues from the Company exceed a certain threshold in 2022, subject to customary working capital and other adjustments as of the closing of the Merger (the "Closing").

DarioHealth Announces Closing of wayForward Acquisition

Study results to be presented at the 14th International Conference on Advanced Technologies and Treatments for Diabetes NEW YORK, June 4, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it will be presenting results of a new study at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2021; June 2-5, 2021). The study, titled "Impact of Digital Intervention Engine on Diabetes Self-Management," examined the effect of DarioHealth's highly personalized digital journeys on both clinical and engagement outcomes, applying user-specific digital intervention flows for behavioral change to increase user digital engagement.

DarioHealth Releases Study Demonstrating the Impact of Personalized Digital Interventions to Improve Self-Management of Diabetes

NEW YORK, June 3, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the company plans to participate in the upcoming Stifel 2021 Virtual Cross Sector Insight Conference.     Erez Raphael, Chief Executive Officer, and Rick Anderson, President and General manager of North America are scheduled to present in a virtual setting on Wednesday, June 9 th, 2021 at 8:00 a.m.

DarioHealth to Participate in the Stifel 2021 Virtual Cross Sector Insight Conference

NEW YORK,, May 27, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced the publication of a new study through a Letter to the Editor in the Journal of Diabetes Science and Technology. The study is titled "Digital Therapeutics for Type 2 Diabetes: Incorporating Coaching Support and Validating Digital Monitoring.

DarioHealth Publishes Research Confirming the Impact of a Digital Therapeutic Platform and Live Coaching on Diabetes Outcomes

NEW YORK, May 26, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that management will participate in the 18th Annual Craig-Hallum Institutional Investor Conference, which is being held virtually on Wednesday, June 2.       Erez Raphael, Chief Executive Officer, and Rick Anderson, President and General Manager of North America, will host investor 1x1 and small group meetings with registered attendees.

DarioHealth to Participate in the Virtual 18th Annual Craig-Hallum Institutional Investor Conference

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q1 2021 Results - Earnings Call Transcript

DarioHealth Corp (NASDAQ: DRIO) has agreed to acquire PsyInnovations Inc (dba wayForward), a behavioral health digital platform, for $30 million. wayForward is currently providing its full suite of digital behavioral health services to approximately 20,000 members and 20 self-insured employers.

DarioHealth Scoops Up Digital Behavioral Health Platform For $30M

NEW YORK, May 18, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has entered into an agreement to acquire PsyInnovations, Inc. (dba wayForward), a behavioral health digital platform that includes AI-enabled screening to triage and navigate members to specific interventions, digital Cognitive Behavioral Therapy (CBT), self-directed care, expert coaching and access to in-person and telehealth provider visits.  The wayForward platform fills an all too common hole in existing behavioral health coverage for people who may not need or be able to access provider-based treatment.

DarioHealth Acquires Digital Behavioral Health Platform wayForward

NEW YORK, May 17, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the first quarter of 2021 and provided a corporate and commercial update. "During the first quarter, we delivered exceptional financial and operating results, driven by balanced contribution from organic growth and the acquisition of Upright Technologies, which we closed on February 2, 2021," stated Erez Raphael, Chief Executive Officer of Dario.

DarioHealth Reports First Quarter 2021 Results and Operational Highlights

NEW YORK, May 10, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the first quarter ended March 31, 2021 on Monday, May 17, 2021, after market close and host a conference call and webcast on Tuesday May 18, at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, Rick Anderson, President and General Manager of North America, and Zvi Ben-David, Chief Financial Officer will host the call.

DarioHealth to Report First Quarter 2021 Results on Monday, May 17

NEW YORK, April 20, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of a new virtual care initiative with MediOrbis, a telehealth provider specializing in chronic conditions.  Eligible Medicare members who have diabetes can receive convenient virtual care for their diabetes, including telehealth delivered by MediOrbis and remote patient monitoring through DarioHealth's AI-powered digital chronic care platform under their existing Medicare benefit.

DarioHealth Partners with MediOrbis on Virtual Care Offering for Diabetes

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q4 2020 Results - Earnings Call Transcript

NEW YORK, March 9, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the fourth quarter and full year 2020 and provided a corporate and commercial update. "The year 2020 was transformational for...

DarioHealth Reports Fourth Quarter and Full Year 2020 Results and Operational Highlights

DarioHealth (NASDAQ:DRIO) releases its next round of earnings this Tuesday, March 09. Here is Benzinga's essential guide to DarioHealth's Q4 earnings report.

A Preview Of DarioHealth's Earnings

NEW YORK, March 1, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the fourth quarter and full year ended December 31, 2020 on Tuesday, March 9, 2021, and host a...

DarioHealth to Report Fourth Quarter and Full Year 2020 Results on Tuesday, March 9

Over the last couple of months, DRIO has continued to sign new contracts in each of its B2B channels, showing strong commercial momentum.

DarioHealth: Upright Acquisition A Game Changer

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that Erez Raphael, Chief Executive Officer, is scheduled to participate and host investor meetings at the 10th Annual SVB Leerink Global...

DarioHealth to Participate in 10th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Jan. 27, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today the signing of a definitive agreement to acquire digital musculoskeletal (MSK) company Upright Technologies Ltd. in a stock transaction....

DarioHealth Announces Acquisition of Leading Digital Musculoskeletal Company Upright Technologies and $70 Million Financing

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation on behalf of DarioHealth Corp. (Nasdaq: DRIO) concerning the Company and its directors' and officers' possible violations of state laws. If you purchased DarioHealth stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 530, New York, NY

Glancy Prongay & Murray LLP Announces Investigation on Behalf of DarioHealth Corp.

NEW YORK, Dec. 22, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the Company has entered into an agreement to provide its remote patient monitoring (RPM) solution to Presbyterian Medical Services, one...

DarioHealth Announces Agreement with Presbyterian Medical Services for Remote Patient Monitoring

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q3 2020 Results - Earnings Call Transcript

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the third quarter 2020 and provided a corporate and commercial update. "During the third quarter we achieved 14.2% sequential...

DarioHealth Reports Third Quarter 2020 Results

DRIO offers a diabetes management solution that is highly rated, provides strong ROI for all parties, and simpler than main competitor Livongo. Seasoned executives in the digital therapeutics space have recently joined DRIO, which helps to validate the new strategy of the company.

DarioHealth: Don't Overlook This Mini Livongo

NEW YORK, Oct. 13, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced that Vitality Group has chosen the company's digital therapeutics solutions for inclusion in Vitality's new Gateway Flex offering. Gateway Flex enables...

DarioHealth Announces Inclusion of its Digital Therapeutics Platform in Vitality Group's New Gateway Flex Offering

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q2 2020 Results - Earnings Call Transcript

News for DarioHealth Stock (DRIO)